SCHEMBL23731963

SCHEMBL23731963

C1CC(C2CCCNC2)C1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SLC6A1 P30531 2/20 0.41
SLC6A11 P48066 1/20 0.41
TSHR P16473 1/20 0.41
LMNA P02545 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
SLC6A13 Q9NSD5 1/20 0.41
HTR2C P28335 1/20 0.39
APLNR P35414 2/20 0.39
KDM4E B2RXH2 1/20 0.39
MAPT P10636 1/20 0.39
KMT2A Q03164 1/20 0.39
ATM Q13315 1/20 0.39
NOS2 P35228 1/20 0.39
CYP2D6 P10635 1/20 0.39
ALDH1A1 P00352 1/20 0.39
CCR5 P51681 1/20 0.37
CPN1 P15169 1/20 0.31
CPB2 Q96IY4 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11577079 1.00 SLC6A1 (0.41) SLC6A1SLC6A11TSHRLMNASMN1; SMN2
SCHEMBL11547731 1.00 SLC6A1 (0.41) SLC6A1SLC6A11TSHRLMNASMN1; SMN2
SCHEMBL6630533 1.00 SLC6A1 (0.41) SLC6A1SLC6A11TSHRLMNASMN1; SMN2
SCHEMBL16877745 0.94
SCHEMBL6631735 0.94 ALDH1A1 (0.47) SLC6A1SLC6A11TSHRLMNASMN1; SMN2
SCHEMBL6096270 0.94 ALDH1A1 (0.47) SLC6A1SLC6A11TSHRLMNASMN1; SMN2
SCHEMBL6914056 0.94
SCHEMBL14119931 0.94
SCHEMBL660990 0.94 SLC6A1 (0.44) SLC6A1SLC6A11TSHRLMNASMN1; SMN2
Chloromethane SCHEMBL23705574 0.92 SLC6A1 (0.37) SLC6A1SLC6A11TSHRLMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12540134-B2 Inhibitors of adrenoreceptor ADRAC2 BAYER AKTIENGESELLSCHAFT (DE) 2026-02-03 US disclosed
EP-4618755-A1 INHIBITORS AND DEGRADERS OF PIP4K PROTEIN Larkspur Biosciences, Inc. (US) 2025-09-24 EP disclosed
WO-2024107746-A1 INHIBITORS AND DEGRADERS OF PIP4K PROTEIN LARKSPUR BIOSCIENCES (US) 2024-05-23 WO disclosed
US-20230115270-A1 INHIBITORS OF ADRENORECEPTOR ADRAC2 BAYER AKTIENGESELLSCHAFT (DE) 2023-04-13 US disclosed
WO-2021155264-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2021-08-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12540134-B2 Inhibitors of adrenoreceptor ADRAC2 ADRA2C, ADRB3, ADRB2 SLC6A1 2552/4885SLC6A11 2625/4885TSHR 613/4885
US-20230115270-A1 INHIBITORS OF ADRENORECEPTOR ADRAC2 ADRA2C, ADRB2, ADRB3 SLC6A1 3806/4885SLC6A11 3455/4885TSHR 1322/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.